StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) income statement

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics, Inc income statement

Ratios

Latest available, balances at Mar 31, 2026

Profitability, TTM

Gross margin
–
Operating margin
-357.5%
Net margin
-356.9%
Return on equity, FY2025
-2891.8%

Financial strength

Current ratio
0.70
Debt to equity
–
Debt to assets
–
Cash to current liabilities
51.9%

Valuation

P/E ratio
–
Price to sales
1.14
Price to book
–
Dividend yield
–

See a number that looks wrong?